ABBVIE
Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05475821
- Locations
- 🇺🇸
Acpru /Id# 247995, Grayslake, Illinois, United States
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT05456685
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States
A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 198
- Registration Number
- NCT05454033
- Locations
- 🇨🇳
The Third Affiliated Hospital, Sun Yat-Sen University /ID# 231398, Guangzhou, Guangdong, China
🇨🇳China-Japan Friendship Hospital /ID# 252139, Beijing, Beijing, China
🇨🇳Plastic Surgery Hospital(Institute), Cams, Pumc /ID# 231394, Beijing, Beijing, China
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
- Conditions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT05451316
- Locations
- 🇯🇵
Tohoku Medical and Pharmaceuti /ID# 252486, Sendai-shi, Miyagi, Japan
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 418
- Registration Number
- NCT05445778
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Texas Oncology - San Antonio (USOR), San Antonio, Texas, United States
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
- Conditions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 998
- Registration Number
- NCT05444972
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires /ID# 244373, Ciudad Autonoma Buenos Aires, Ciuadad Autonoma De Buenos Aires, Argentina
🇦🇷Fundaleu /Id# 244371, Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
🇮🇹Azienda Ospedaliera di Perugia /ID# 245415, Perugia, Umbria, Italy
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 161
- Registration Number
- NCT05439616
- Locations
- 🇺🇸
Cincinnati Children's Hospital /ID# 243968, Cincinnati, Ohio, United States
🇺🇸Core Clinical Research /ID# 243084, Everett, Washington, United States
🇺🇸Family Psychiatry of The Woodlands /ID# 242867, The Woodlands, Texas, United States
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
- Conditions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 270
- Registration Number
- NCT05424562
- Locations
- 🇨🇦
BC Cancer - Victoria /ID# 257339, Victoria, British Columbia, Canada
🇨🇦BC Cancer - Surrey /ID# 257515, Surrey, British Columbia, Canada
🇨🇦Vancouver General Hospital /ID# 245438, Vancouver, British Columbia, Canada
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 87
- Registration Number
- NCT05414201
- Locations
- 🇨🇳
Peking University First Hospital /ID# 243055, Beijing, Beijing, China
🇨🇳Tianjin Medical University Eye Hospital /ID# 243056, Tianjin, China
🇨🇳The second affiliated hospital of Zhejiang University school of medicine /ID# 247251, Hangzhou, Zhejiang, China
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 65
- Registration Number
- NCT05411198
- Locations
- 🇺🇸
Vold Vision /ID# 245285, Fayetteville, Arkansas, United States
🇺🇸UCLA Doheny Eye Center /ID# 227587, Pasadena, California, United States
🇺🇸Ventura Ophthalmology /ID# 227585, Ventura, California, United States